AstraZeneca has strengthened its oncology pipeline by signing an exclusive global licensing agreement worth up to $1.5 billion with Chinese biotechnology company Dizal Pharmaceutical for the lung cancer treatment Zegfrovy (sunvozertinib). According to Reuters, the British pharmaceutical giant will pay $600 million upfront, with Dizal eligible to receive up to $900 million in development, regulatory, and commercial milestone payments, alongside tiered royalties on future sales. The agreement grants AstraZeneca worldwide rights to develop and commercialise the medicine outside China.
Zegfrovy is designed to treat patients with non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations, a difficult-to-treat form of the disease with limited therapeutic options. The medicine has already received regulatory approval in China and the United States for certain patients with advanced or metastatic NSCLC whose disease has progressed after previous treatment. AstraZeneca said the acquisition complements its growing precision oncology portfolio and reinforces its commitment to expanding access to targeted cancer therapies globally.
The transaction reflects the increasing influence of China’s biotechnology sector in global drug development, with multinational pharmaceutical companies pursuing innovative therapies developed by Chinese firms. The deal is expected to close during the second half of 2026, subject to customary regulatory approvals, and AstraZeneca said it will not affect its financial guidance for the year. For Dizal, the partnership provides significant capital to accelerate research while leveraging AstraZeneca’s global development, manufacturing, and commercial capabilities.
For AstraZeneca, the agreement strengthens one of the world’s largest oncology portfolios and reinforces its strategy of acquiring innovative medicines through strategic licensing partnerships rather than relying solely on in-house research. Analysts say the collaboration highlights the growing role of Chinese biopharmaceutical innovation in the global healthcare industry and could accelerate the availability of targeted treatments for lung cancer patients worldwide.
